Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What they are saying: PASTEUR Act can help fight antimicrobial resistance

By Andrew Powaleny  |    November 30, 2022
Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and 1.27 million globally on an annual basis – higher than HIV/AIDS and malaria. To slow and...   Read More

Putting Delaware patients first: Protecting Patient Assistance Programs

By Stami Williams  |    November 22, 2022
Patients with chronic health conditions in Delaware are seeing a new wave of relief thanks to Governor John Carney, members of the Delaware legislature and more than 40 patient groups. The recently...   Read More

How HTA-based price controls could worsen health outcomes and health disparities

By Katie Koziara  |    November 22, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

By Nicole Longo  |    November 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times...   Read More

Medicare Part D open enrollment and what recent changes mean for beneficiaries

By Nicole Longo  |    November 17, 2022
It’s that time of year again: Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their...   Read More

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

By Megan Van Etten  |    November 17, 2022
The United States has led the charge in the development of vaccines and treatments to combat COVID-19 thanks in large part to our robust innovation ecosystem, supported by intellectual property (IP)...   Read More

Six ways I-MAK is lying about biopharma patents

By Megan Van Etten  |    November 16, 2022
The Arnold-Venture funded advocacy group Initiative for Medicines, Access & Knowledge, Inc. (or I-MAK) is on a global media tour, espousing their point of view on the patent system. Some experts and...   Read More

New data show how insurers and middlemen shift Rx costs onto patients

By Brian Newell  |    November 16, 2022
There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that’s at the pharmacy counter. A new report reveals how this harmful tactic...   Read More

What you should know about RSV

By Michael Ybarra  |    November 15, 2022
You are probably reading a lot about a surge of cases of respiratory viruses like respiratory syncytial virus (RSV), influenza (the flu) and SARS-CoV-2, which causes COVID-19. The triple threat of...   Read More

TRIPS waiver expansion risks public health

By Megan Van Etten  |    November 14, 2022
The Biden administration and other World Trade Organization members are considering expanding the harmful and unnecessary waiver of intellectual property (IP) protections under the Agreement on...   Read More

New government price setting policy threatens post-approval research

By Nicole Longo  |    November 10, 2022
Have you ever noticed that one medicine might be used to treat two, three, seven different conditions? That’s the result of significant additional research and investment, including lengthy and...   Read More

Congratulations to our 2022 Working for Cures Employee Champions

By Stephen J. Ubl  |    November 10, 2022
The Working for Cures Employee Champion Awards celebrate the real people in our industry who go above and beyond to advance science and support the work our industry does for patients.   Read More

Expanding the WTO intellectual property waiver will hurt American jobs

By Megan Van Etten  |    November 9, 2022
The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was...   Read More

ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research

By Emilie Signora  |    November 8, 2022
Our health care ecosystem has made tremendous progress in the fight against cancer, with the cancer death rate falling 32% from its peak in 1991. On November 3, PhRMA sponsored The Atlantic’s People...   Read More

Traditional HTA methods treat everyone like the “average” patient

By Katie Koziara  |    November 7, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

New paper: Addressing the growing crisis of mental health and substance use disorders

By Lindsey Seidlitz  |    November 7, 2022
The United States is facing a crisis of mental health and addiction that has left few Americans and families unimpacted by these illnesses and the devastating consequences that are often associated...   Read More

PhRMA submission to USTR calls for urgent defense of American innovation abroad

By Douglas Petersen  |    November 1, 2022
The United States leads the world in medicine research, development and manufacturing, and international trade delivers those medicines to patients around the globe. But trade barriers imposed in...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates